CRXL: Crucell NV StockTalks

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, July 17, 2012, 8:12 AM More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR) Comment! [Earnings, Top Stories, Healthcare]
Friday, December 10, 2010, 11:44 AM Crucell (CRXL) CEO Robert Brus works to put down a rebellion by big shareholders - including 10% holder Van Herk Groep - saying that accepting a €1.75B bid from Johnson & Johnson (JNJ) means funded research and preserving the company's identity as a vaccines center within JNJ. Opponents say €24.75/share is too low and the product pipeline will yield strong results over five to eight years. Comment!
Wednesday, December 8, 2010, 8:02 AM J&J (JNJ) formally launches its €1.75B ($2.3B) bid for Crucell (CRXL), despite objections from some of Crucell's shareholders. J&J wants control of Crucell's vaccine pipeline at a time when vaccine sales are outstripping those of prescription drugs and face less competition from generics. (previously) Comment!
Wednesday, October 6, 2010, 7:31 AM J&J (JNJ) and Crucell (CRXL +0.75%) agree to move forward with J&J's ~€1.75B offer for the shares of the Dutch biotech firm it doesn't already own, despite some shareholder objections. J&J will get control of Crucell's vaccine pipeline at a time when vaccine sales are outstripping those of prescription drugs and face less competition from generics. Comment!
Friday, September 17, 2010, 9:00 AM Premarket gainers: CRXL +55%. CBLI +17%. ALKS +5%. ORCL +4%. RIMM +4%.
Losers: ARNA -45%. OREX -8%. VVUS -5%. ERIC -5%. IRE -4%. RBY -4%. 1 Comment
Friday, September 17, 2010, 7:31 AM J&J (JNJ) is in advanced talks to buy the shares of Crucell (CRXL) it doesn't already own for around €1.75B ($2.3B) in cash, or €24.75/share. The offer is a 58% premium to Crucell's closing price yesterday in Amsterdam. Premarket: CRXL +54%. (PR) Comment!
Wednesday, May 6, 2009, 9:00 AM Premarket gainers: APAC +38%. ARM +23%. CKSW +22%. ACOR +21%. CROX +17%. AIB +17%. CTIC +16%. SUMT +17%. FIG +14%. LNC +14%. BEE +13%. ABK +11%. DAN +11%. PLT +11%. BYD +11%. HOV +9%. SRZ +9%. GNW +10%. ANR +8%. DIS +7%. CLF +7%. KFN +7%. BZH +7%. BAC +7%. HBC +6%. FITB +6%. BRCD +6%. BX +6%. DRYS +6%. HIG +5%. WFC +5%. EXM +5%. HMY +5%. ALU +5%. MGM +5%. COF +5%. AU +5%. CRXL +5%. GFI +5%. GERN +5%. Comment!
Monday, April 27, 2009, 9:02 AM Premarket gainers on swine-flu speculation: NVAX +133%. SVA +63%. BCRX +58%. AVII +35%. VICL +32%. QDEL +26%. HGSI +19%. RAD +15%. CRXL +7%. BLUD +7%. HUM +6%. BAX +4%. GSK +4%. THC +4%. GILD +4%. 1 Comment
Thursday, February 19, 2009, 9:03 AM Premarket losers: BRMN -19%. EXPE -14%. LDK -8%. CCJ -8%. BNI -4%. CRXL -4%. SHPGY -4%. HPQ -3%. Comment!
Tuesday, February 17, 2009, 9:00 AM Premarket losers: lyg -21%. MTG -17%. AEE -16%. AEG -15%. MTL -13%. DB -13%. ING -13%. MT -11%. FAS -11%. BHP -10%. IBN -10%. BAC -9%. RBS -9%. MGM -8%. DAI -8%. AAUK -8%. PHG -8%. CS -8%. CRXL -8%. WFC -8%. LVS -7%. UBS -7%. HBC -7%. WFT -7%. GM -7%. AMAG -7%. ABB -7%. STI -7%. DE -7%. Comment!
Monday, February 2, 2009, 10:46 AM Sanofi-aventis's (SNY) new CEO Chris Viehbacher says he's a buyer, and has held talks with bankers regarding funding. Possible targets include Bristol-Myers (BMY), Amgen (AMGN), Biogen Idec (BIIB) and Crucell (CRXL). Comment!
Monday, January 26, 2009, 9:00 AM Premarket losers: ROH -16%. CRXL -15%. CAT -7%. TEX -7%. DE -5%. PFE -4%. KMB -3%. FCX -3%. Comment!
Friday, January 23, 2009, 9:01 AM Premarket losers: HOG -19%. BCS -19%. COF -14%. CRXL -12%. ING -11%. DRYS -10%. MT -10%. HBAN -10%. JASO -10%. FITB -9%. RBS -8%. WFR -8%. BAC -8%. JBLU -8%. SAP -7%. PHG -7%. JPM -6%. UBS -6%. SI -6%. BP -6%. USB -6%. RTP -6%. ABB -6%. WFC -6%. BHP -6%. AAUK -6%. ASML -6%. RF -6%. Comment!
Thursday, January 8, 2009, 9:00 AM Premarket gainers: SWIM +40%. SHLD +11.5%. WFMI +8.5%. GME +7.5%. CRXL +7%. BLUD +6%. URBN +6%. ARO +4.5%. HMY +4%. GFI +4%. EMC +4%. SYT +4%. GG +4%. Comment!
Thursday, January 8, 2009, 7:26 AM Wyeth (WYE) is in talks to buy Dutch vaccine maker Crucell (CRXL), part of its efforts to gain market share in one of the fastest growing parts of the industry. Sources say a deal valuing Crucell at over €1B ($1.35B) could be reached as early as next week. Comment!

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
J&J Launches Public Offer for Crucell Shares $JNJ $CRXL
12/8/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Mays Report
J.&J.(JNJ) Bids $2.3 Billion for Crucell (CRXL).
12/8/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Smart-Ticker.com
Last hour bears $NUVA,$DRC,$AMAG,$QSII,$PWER,$OCLR,$CRXL,$GNW,$WMGI,$NVTL...more http://s-t.cc
10/29/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

CRXL Crucell NV

CRXL

Crucell NV